176 related articles for article (PubMed ID: 27857131)
1. Epigenetic silencing of miR-137 induces drug resistance and chromosomal instability by targeting AURKA in multiple myeloma.
Qin Y; Zhang S; Deng S; An G; Qin X; Li F; Xu Y; Hao M; Yang Y; Zhou W; Chang H; Qiu L
Leukemia; 2017 May; 31(5):1123-1135. PubMed ID: 27857131
[TBL] [Abstract][Full Text] [Related]
2. miR-520g and miR-520h overcome bortezomib resistance in multiple myeloma via suppressing APE1.
Yuan X; Ma R; Yang S; Jiang L; Wang Z; Zhu Z; Li H
Cell Cycle; 2019 Jul; 18(14):1660-1669. PubMed ID: 31204563
[No Abstract] [Full Text] [Related]
3. Ectopic expression of BIRC5-targeting miR-101-3p overcomes bone marrow stroma-mediated drug resistance in multiple myeloma cells.
Abdi J; Rastgoo N; Chen Y; Chen GA; Chang H
BMC Cancer; 2019 Oct; 19(1):975. PubMed ID: 31638931
[TBL] [Abstract][Full Text] [Related]
4. Targeting the miR-221-222/PUMA/BAK/BAX Pathway Abrogates Dexamethasone Resistance in Multiple Myeloma.
Zhao JJ; Chu ZB; Hu Y; Lin J; Wang Z; Jiang M; Chen M; Wang X; Kang Y; Zhou Y; Ni Chonghaile T; Johncilla ME; Tai YT; Cheng JQ; Letai A; Munshi NC; Anderson KC; Carrasco RD
Cancer Res; 2015 Oct; 75(20):4384-4397. PubMed ID: 26249174
[TBL] [Abstract][Full Text] [Related]
5. hsa-miR-631 resensitizes bortezomib-resistant multiple myeloma cell lines by inhibiting UbcH10.
Xi H; Li L; Du J; An R; Fan R; Lu J; Wu YX; Wu SX; Hou J; Zhao LM
Oncol Rep; 2017 Feb; 37(2):961-968. PubMed ID: 28000886
[TBL] [Abstract][Full Text] [Related]
6. Targeting of CD38 by the Tumor Suppressor miR-26a Serves as a Novel Potential Therapeutic Agent in Multiple Myeloma.
Hu Y; Liu H; Fang C; Li C; Xhyliu F; Dysert H; Bodo J; Habermehl G; Russell BE; Li W; Chappell M; Jiang X; Ondrejka SL; Hsi ED; Maciejewski JP; Yi Q; Anderson KC; Munshi NC; Ao G; Valent JN; Lin J; Zhao J
Cancer Res; 2020 May; 80(10):2031-2044. PubMed ID: 32193289
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-324-5p regulates stemness, pathogenesis and sensitivity to bortezomib in multiple myeloma cells by targeting hedgehog signaling.
Tang B; Xu A; Xu J; Huang H; Chen L; Su Y; Zhang L; Li J; Fan F; Deng J; Tang L; Sun C; Hu Y
Int J Cancer; 2018 Jan; 142(1):109-120. PubMed ID: 28905994
[TBL] [Abstract][Full Text] [Related]
8. Study on the Association Between miRNA-202 Expression and Drug Sensitivity in Multiple Myeloma Cells.
Shen X; Guo Y; Qi J; Shi W; Wu X; Ni H; Ju S
Pathol Oncol Res; 2016 Jul; 22(3):531-9. PubMed ID: 26689580
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma.
Amodio N; Stamato MA; Gullà AM; Morelli E; Romeo E; Raimondi L; Pitari MR; Ferrandino I; Misso G; Caraglia M; Perrotta I; Neri A; Fulciniti M; Rolfo C; Anderson KC; Munshi NC; Tagliaferri P; Tassone P
Mol Cancer Ther; 2016 Jun; 15(6):1364-75. PubMed ID: 27196750
[TBL] [Abstract][Full Text] [Related]
10. miR-182 contributes to cell adhesion-mediated drug resistance in multiple myeloma via targeting PDCD4.
Wu Y; Zhu X; Shen R; Huang J; Xu X; He S
Pathol Res Pract; 2019 Nov; 215(11):152603. PubMed ID: 31540771
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic silencing of LPP/miR-28 in multiple myeloma.
Li Z; Wong KY; Chan GC; Chim CS
J Clin Pathol; 2018 Mar; 71(3):253-258. PubMed ID: 28775176
[TBL] [Abstract][Full Text] [Related]
12. Genome-wide pharmacologic unmasking identifies tumor suppressive microRNAs in multiple myeloma.
Bi C; Chung TH; Huang G; Zhou J; Yan J; Ahmann GJ; Fonseca R; Chng WJ
Oncotarget; 2015 Sep; 6(28):26508-18. PubMed ID: 26164366
[TBL] [Abstract][Full Text] [Related]
13. miR-15a and miR-16 affect the angiogenesis of multiple myeloma by targeting VEGF.
Sun CY; She XM; Qin Y; Chu ZB; Chen L; Ai LS; Zhang L; Hu Y
Carcinogenesis; 2013 Feb; 34(2):426-35. PubMed ID: 23104180
[TBL] [Abstract][Full Text] [Related]
14. MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine.
Xiang Y; Ma N; Wang D; Zhang Y; Zhou J; Wu G; Zhao R; Huang H; Wang X; Qiao Y; Li F; Han D; Wang L; Zhang G; Gao X
Oncogene; 2014 Jan; 33(3):378-86. PubMed ID: 23318422
[TBL] [Abstract][Full Text] [Related]
15. miR-137 suppresses tumor growth of malignant melanoma by targeting aurora kinase A.
Chang X; Zhang H; Lian S; Zhu W
Biochem Biophys Res Commun; 2016 Jul; 475(3):251-6. PubMed ID: 27233613
[TBL] [Abstract][Full Text] [Related]
16. A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells.
Leotta M; Biamonte L; Raimondi L; Ronchetti D; Di Martino MT; Botta C; Leone E; Pitari MR; Neri A; Giordano A; Tagliaferri P; Tassone P; Amodio N
J Cell Physiol; 2014 Dec; 229(12):2106-16. PubMed ID: 24819167
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-124-3p affects proliferation, migration and apoptosis of bladder cancer cells through targeting AURKA.
Yuan Q; Sun T; Ye F; Kong W; Jin H
Cancer Biomark; 2017; 19(1):93-101. PubMed ID: 28269755
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic silencing of miR-335 induces migration by targeting insulin-like growth factor-1 receptor in multiple myeloma.
Qi J; Shi LY; Wu Y; Shen XJ; Yuan J; Jin CJ; Cong H; Ju SQ
Leuk Lymphoma; 2019 Dec; 60(13):3188-3198. PubMed ID: 31190579
[TBL] [Abstract][Full Text] [Related]
19. miR-137 and miR-197 Induce Apoptosis and Suppress Tumorigenicity by Targeting MCL-1 in Multiple Myeloma.
Yang Y; Li F; Saha MN; Abdi J; Qiu L; Chang H
Clin Cancer Res; 2015 May; 21(10):2399-411. PubMed ID: 25724519
[TBL] [Abstract][Full Text] [Related]
20. miR-17-92 cluster microRNAs confers tumorigenicity in multiple myeloma.
Chen L; Li C; Zhang R; Gao X; Qu X; Zhao M; Qiao C; Xu J; Li J
Cancer Lett; 2011 Oct; 309(1):62-70. PubMed ID: 21664042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
